Our use of C-peptide level as a marker of insulin resistance, rather than the HOMAIR (using insulin and glucose measures), was justified as C-peptide is a validated marker of hyperinsulinaemia [9] and has been previously associated with colorectal cancer risk [11,12]. This evidence concerns the gene INS and Insulin resistance.